Nrg Lu-003: A Biomarker Driven Protocol For Previously Treated Alk-Mutation Positive Non-Squamous, Non-Small Cell Lung Cancer - A Nci-Nrg Alk Master Protocol
Posted Date: Feb 5, 2020
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
- Type of Study: Drug
The purpose of this study is to assess whether ALK mutations in non-small cell lung cancers, which are usually associated with drug resistance, are prognostic for a response to ALK inhibitor therapy and to evaluate objective responses of patients with specific genetic alterations treated with crizotinib targeted therapy.
Criteria:
Stage Iv Alk-Positive Adenocarcinoma Non-Small Cell Lung Cancer 18 Years Or Older With Progressive Disease
Keywords:
Lung Cancer, Non-Small Cell Lung Cancer, Alk Mutations
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com